October 31, 2024
Shanghai Henlius Biotech, Organon announce FDA acceptance of BLA for HLX14
Shanghai Henlius Biotech (Henlius) and Organon have announced the US Food and Drug Administration (FDA) acceptance of the biologic license application (BLA) for HLX14, a biosimilar candidate of PROLIA/XGEVA (denosumab).